Q1 2026 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc (FLGT) successfully completed the acquisition of Bako Diagnostics and StrataDx, which contributed positively to their first-quarter results.
- The company is seeing accelerated progress in its therapeutic development pipeline, particularly with its clinical candidate FID-007 advancing through Phase 2 trials.
- Fulgent Genetics Inc (FLGT) has integrated Illumina's TruPath Genome, enhancing their whole genome test capabilities and targeting complex variant classes.
- The company received MolDX approval and pricing for their PGx test, aligning with recent ASCO recommendations for pharmacogenomic testing.
- Fulgent Genetics Inc (FLGT) is in a strong financial position, with a significant cash reserve and ongoing stock repurchase program, indicating confidence in their strategy and value.
- Revenue for the first-quarter of 2026 decreased by 3.6% year-over-year and 14.6% quarter-over-quarter, primarily due to a reduction in sales to their largest customer.
- The company's GAAP gross margin declined to 30.2%, reflecting fixed costs over a lower revenue base.
- Non-GAAP operating margin decreased to a negative 27.7% due to decreased revenue.
- Fulgent Genetics Inc (FLGT) reported a GAAP loss of $24.8 million for the current quarter, an increase from the prior quarter.
- The company experienced delays in receiving a $106 million federal income tax refund, impacting their cash flow.
Greetings. Welcome to Fulgent Genetics first-quarter 2026 conference call and webcast.
(Operator Instructions)
Please note, this conference is being recorded. I will now turn the conference over to Lauren Sloane, Investor Relations. Thank you. You may begin.
Good morning, and welcome to Fulgent's first-quarter 2026 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing the financial results is available on the Investor Relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website.
Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on current views,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
